{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004482","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.557332+00:00","generated_at":"2026-05-31T12:27:13.503524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4","bullets":["Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.","Net income of $5.1M ($0.03/sh) vs net loss of $18.8M (-$0.43) YoY; non-cash warrant income $30.5M.","R&D spend $21.1M (+26% YoY) on clinical trial costs; G&A $6.4M (-30% YoY).","ALG-055009 (MASH) HERALD enrollment complete; topline data expected early Q4 2024.","ALG-000184 (CHB) showed sustained HBV DNA suppression in 90-100% of subjects; FDA supports registration endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004482","json":"https://secwatch.observer/filing/0001171843-24-004482.json","markdown":"https://secwatch.observer/filing/0001171843-24-004482.md","text":"https://secwatch.observer/filing/0001171843-24-004482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324004482/0001171843-24-004482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324004482/f8k_080624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:27:13.503524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}